thirty-nine patients were entered into a 12-week , randomized , double-blind , parallel protocol to assess the safety and efficacy of enalapril ( mk-421 , 10 to 20 mg bid ) , hydrochlorothiazide ( hctz , 25 to 50 mg bid ) , or combined drug therapy ( mk-421 + hctz ) for the treatment of primary hypertension .
C0020261
hctz
C0020538
hypertension